Minimally Invasive Needle-Based Biopsy Instruments Drive Growth in the Biopsy Devices Market, Offering Precision and Patient Comfort - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Biopsy Devices Market 2023-2027" report has been added to ResearchAndMarkets.com's offering.

The global biopsy devices market is poised to achieve a projected value of $11.86 billion by 2027, representing a remarkable Compound Annual Growth Rate (CAGR) of 15.15% during the forecast period from 2023 to 2027. Key drivers contributing to this growth include a surge in cancer incidence, the versatility of biopsy procedures, and government initiatives for early cancer detection.

Industry Impact

The biopsy devices market has significantly impacted the healthcare industry through several key developments:

• Shift to Minimally Invasive Biopsies: The market has witnessed a notable shift from conventional surgical biopsies to minimally invasive needle-based biopsy instruments. This transition has reduced patient discomfort, accelerated recovery times, and expanded the scope of biopsy procedures beyond cancer diagnosis to include liver diseases, infectious diseases, autoimmune disorders, and therapeutic monitoring.
• Improved Accuracy and Precision: Biopsy devices have evolved to offer increased accuracy and precision, enabling earlier and more accurate disease diagnosis, particularly in cases of cancer.
• Enhanced Patient Outcomes: By improving the accuracy, precision, and accessibility of biopsy procedures, these devices have contributed to better patient outcomes across various medical conditions.
• Integration of Advanced Imaging Technologies: The integration of advanced imaging technologies with biopsy procedures is revolutionizing diagnostics and treatment. This approach enhances precision, reduces invasiveness, and improves patient recovery outcomes.
• Research and Development: The continuous growth of the biopsy market has spurred ongoing research and development efforts to explore new technologies and delivery methods, further enhancing patient diagnosis, treatment, and recovery.

Market Segmentation

The global biopsy devices market is segmented as follows:

1. By Product:

• Tissue Biopsy (Tissue Biopsy Devices, Consumables)
• Liquid Biopsy (Test Service, Kits, Platforms, Consumables)

2. By Biopsy Type:

• Tissue Biopsy (Needle Biopsy, Skin Biopsy, Surgical Biopsy)
• Liquid Biopsy

3. By Disease Type:

• Tissue Biopsy (Cancer, Infections, Autoimmune Disorders, Others)
• Liquid Biopsy (Cancer, Non-Cancerous Indications)

4. By Anatomy:

• Tissue Biopsy (Breast, Lung, Bone, Liver, Uterus/Cervix/Ovary, Abdomen, Prostate, Cardiac, Skin, Others)
• Liquid Biopsy (Breast, Lung, Prostate, Others)

5. By Guidance Technique:

• X-Ray-Guided Biopsy
• Ultrasound-Guided Biopsy
• MRI-Guided Biopsy
• CT-Guided Biopsy

6. By Region:

• Americas
• EMEA
• Asia-Pacific

Recent Developments in the Biopsy Devices Market

Key developments in the market include product launches, partnerships, acquisitions, and advancements in biopsy technologies:

Product Launches:

1. In May 2023, Argon Medical Devices, Inc. launched the SuperCore Advantage Semi-Automatic Biopsy instrument, expanding its soft tissue biopsy product portfolio in the U.S.
2. In April 2023, GE Healthcare introduced the bkActiv system for surgical applications, providing surgeons with advanced ultrasound imaging capabilities during surgical procedures.
3. In April 2021, Olympus Corporation expanded its U.S. bronchoscopy product line by introducing the H-SteriScope Single-Use Bronchoscopes, designed for advanced diagnostic and therapeutic procedures.

Partnerships and Collaborations:

1. In May 2022, Terumo India partnered with Argon Medical to provide comprehensive medical solutions, including biopsy tools and deep vein thrombosis treatments, in the Indian market.
2. In July 2022, the Food and Drug Administration granted approval for the incorporation of Siemens Healthineers' mobile imaging technology into Intuitive's robotic-assisted platform for minimally invasive lung biopsies.

Acquisitions:

1. In January 2023, GE Healthcare successfully completed an acquisition agreement with the France-based company IMACTIS, emphasizing the potential of IMACTIS' computerized tomography (CT) navigation product for safety and accuracy.
2. In August 2023, Agilent Technologies Inc. halted the operations of its Resolution Bioscience liquid biopsy division, focusing on other areas of its business.
3. In January 2023, Agilent Technologies Inc. acquired Avida Biomed to enhance its capabilities in the liquid biopsy space.

Advancements in Liquid Biopsy:

1. In September 2023, Dxcover Limited augmented its executive team to further develop its multi-cancer liquid biopsy platform.
2. In February 2023, Dxcover Limited raised $11.9 million in Series A and grant financing to advance its liquid biopsy platform for detecting early-stage cancers.
3. In February 2022, Dxcover Limited secured a U.S. patent for cancer diagnostic devices, including the Dxcover autosampler and the Dxcover brain cancer liquid biopsy.

Key Market Players and Competition

Several key players are actively contributing to the biopsy devices market. Companies profiled in the report include:

• Argon Medical Devices, Inc.
• B. Braun SE
• Becton, Dickinson and Company
• Boston Scientific Corporation
• Cardinal Health, Inc.
• Cook Group Incorporated
• Conmed Corporation
• FUJIFILM Holdings Corporation
• GE Healthcare
• Inrad, Inc.
• Medtronic plc
• Olympus Corporation
• Siemens Healthineers AG
• Stryker Corporation
• Zamar Care
• Changzhou Jiuhong Medical Instrument Co., Ltd.
• Kindly (KDL) Meditech
• Ningbo Xinwell Medical Technology Co., Ltd.
• Shenzhen Manners Technology Co., Ltd.
• Zhejiang Soudon Medical Technology Co., Ltd
• Agilent Technologies, Inc.
• BGI Group
• Biocept, Inc.
• Bio-Rad Laboratories, Inc.
• Dxcover Limited
• Elypta Limited
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Micronoma
• QIAGEN
• Revvity, Inc.
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

Key Attributes:

For more information about this report visit https://www.researchandmarkets.com/r/sk394z

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900